Despite Battling Scale-Up Issues, Phalanx Low-Cost Human-Genome Arrays On Track for 2005 | GenomeWeb

It has been quiet around Phalanx Biotech Group since the Taiwanese company in June announced its introductory offer of a $100 whole-genome human array.

The company’s stated goal is to make commercial microarrays affordable for researchers worldwide by offering them at a price between $100 and $200, much less than the average price of $500-$600 for other whole-genome arrays. And industry observers are guessing whether the firm’s entry into the market will touch off a price war.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.